Cardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Jefferies Financial Group

Research analysts at Jefferies Financial Group began coverage on shares of Cardiff Oncology (NASDAQ:CRDF - Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a "hold" rating and a $3.50 price target on the stock. Jefferies Financial Group's price objective would suggest a potential upside of 10.76% from the stock's previous close.

Several other equities analysts have also recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.88.

Cardiff Oncology Trading Up 1.9%

Shares of CRDF opened at $3.16 on Tuesday. The firm has a market cap of $210.23 million, a PE ratio of -3.43 and a beta of 1.61. Cardiff Oncology has a 1-year low of $2.01 and a 1-year high of $5.64. The firm has a fifty day simple moving average of $3.10 and a two-hundred day simple moving average of $3.56.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 8,308.50% and a negative return on equity of 76.45%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. As a group, research analysts forecast that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Blair William & Co. IL grew its holdings in Cardiff Oncology by 521.0% in the first quarter. Blair William & Co. IL now owns 1,751,274 shares of the company's stock worth $5,499,000 after purchasing an additional 1,469,249 shares during the period. Orbimed Advisors LLC purchased a new stake in shares of Cardiff Oncology during the 4th quarter valued at about $6,677,000. Adage Capital Partners GP L.L.C. increased its position in shares of Cardiff Oncology by 11.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,445,000 shares of the company's stock valued at $4,537,000 after purchasing an additional 152,692 shares during the last quarter. Acorn Capital Advisors LLC bought a new position in Cardiff Oncology during the fourth quarter valued at $6,260,000. Finally, Geode Capital Management LLC grew its stake in Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock worth $4,266,000 after acquiring an additional 54,646 shares in the last quarter. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.